BriaCell Therapeutics Corp. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
BCTX Nasdaq 2830 briacell.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for BriaCell Therapeutics Corp.

BriaCell Announces Rescheduling of its Annual General Meeting of Shareholders to February 5, 2025 - Jan 3rd, 2025 10:05 pm
BriaCell Announces Proposed Effective Date of Share Consolidation - Jan 3rd, 2025 10:05 pm
Insider Purchases Worth US$5.52m See Losses As BriaCell Therapeutics Market Value Drops To CA$40m - Dec 19th, 2024 1:05 pm
BriaCell Announces Availability of Annual General Meeting Materials and Alternative Voting Procedures - Dec 17th, 2024 9:05 pm
BriaPro Therapeutics Corp. Announces Availability of Annual General Meeting Materials and Alternative Voting Procedures - Dec 17th, 2024 9:05 pm
BriaCell Therapeutics Announces Closing of $5.5 Million Public Offering - Dec 13th, 2024 9:05 pm
BriaCell 2024 SABCS® Poster Highlights Ability of Bria-IMT™ Regimen to Increase Cancer-Fighting Immune Cells in Metastatic Breast Cancer - Dec 13th, 2024 12:50 pm
BriaCell Therapeutics Announces Pricing of $5.5 Million Public Offering - Dec 12th, 2024 4:54 am
BriaCell Therapeutics Announces Proposed Public Offering - Dec 11th, 2024 9:05 pm
BriaCell Presents Unprecedented Overall Survival Data in Metastatic Breast Cancer in Spotlight Poster at 2024 SABCS® - Dec 11th, 2024 12:50 pm
BriaCell Receives Green-Light from Data Safety Monitoring Board for its Phase 3 Study in Metastatic Breast Cancer - Dec 2nd, 2024 12:50 pm
BriaCell 2024 SABCS® Spotlight Poster to Showcase Positive Overall Survival Data Across All Patient Subtypes in Metastatic Breast Cancer - Nov 26th, 2024 12:50 pm
BriaCell Provides Update to its Board of Directors - Nov 25th, 2024 12:50 pm
BriaCell Announces First Patient Dosed with Bria-OTS™ in Metastatic Breast Cancer Study - Nov 21st, 2024 12:50 pm
BriaCell Showcases Robust Anti-Cancer Activity of Personalized Off-the-Shelf Immunotherapy Pipeline at the 2024 SITC Conference - Nov 8th, 2024 12:50 pm
BriaCell Overall Survival Data Selected for Spotlight Poster at 2024 San Antonio Breast Cancer Symposium®, December 10 – 13 - Nov 4th, 2024 12:50 pm
BriaCell Higher as it Reports "Standard-Beating" Survival Data From Phase 2 Study - Oct 22nd, 2024 3:06 pm
BriaCell Reports Outperforming Metastatic Breast Cancer Patients and Standard-Beating Survival Data - Oct 22nd, 2024 11:50 am
BriaCell Provides Phase 3 Clinical Engagement Update in Metastatic Breast Cancer Pivotal Study - Oct 15th, 2024 11:50 am
BriaCell Therapeutics Announces Closing of $5 Million Offering - Oct 2nd, 2024 8:05 pm